AI Revolutionizes Urologic Care # Urology has become a critical frontier for artificial intelligence in medicine, particularly in the detection and management of prostate cancer, the most common non-skin cancer in American men. From AI systems that analyze prostate MRI to algorithms that assess biopsy pathology and guide surgical planning, these technologies are fundamentally changing how urologic conditions are diagnosed, staged, and treated. But with transformation comes significant liability exposure: When an AI system fails to detect clinically significant prostate cancer, or when a robotic surgery system contributes to a complication, who bears responsibility?
AI Transforms Cancer Care # Artificial intelligence is reshaping every phase of cancer care, from early detection through treatment planning and survivorship monitoring. AI tools now analyze mammograms for breast cancer, pathology slides for prostate cancer, and imaging studies across multiple cancer types. But as AI becomes embedded in oncology workflows, critical liability questions emerge: When AI-assisted diagnosis misses cancer or delays treatment, who bears responsibility? When AI recommends treatment and outcomes are poor, what standard of care applies?
AI Transforms the Pathology Laboratory # Pathology, the cornerstone of cancer diagnosis, is undergoing a digital revolution. Whole slide imaging has transformed glass slides into gigapixel digital files, and AI algorithms now assist pathologists in detecting cancers, grading tumors, and identifying features invisible to the human eye. Paige AI’s 2021 FDA authorization marked the first-ever approval for AI in pathology, and the field has expanded rapidly since.